Orientador: Mary Luci de Souza Queiroz / Tese ( doutorado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas / Made available in DSpace on 2018-08-12T11:14:50Z (GMT). No. of bitstreams: 1 Ramos_AlineLisie_D.pdf: 13996403 bytes, checksum: 20b3e94e609f9ce6fd4214680378bb52 (MD5) Previous issue date: 2008 / Resumo: A Chlorella vulgaris (CV) é uma alga microscópica bastante rica em nutrientes. Além de alto valor nutritivo, a Chlorella tem demonstrado possuir importantes atividades terapêuticas. Vários trabalhos do nosso laboratório e outros demonstram os efeitos protetores desta alga contra infecções virais e bacterianas, tumores, entre outros. No presente trabalho avaliamos os efeitos do tratamento profilático/terapêutico com a dose de 50mg/Kg/dia de CV sobre a resposta imunohematopoética de animais normais e portadores de tumor ascítico de Ehrlich (TAE). O estudo dos mecanismos envolvidos na proteção produzida pela alga frente às alterações induzidas pelo TAE no sistema imuno-hematopoético, demonstrou aumentos significativos na atividade de células NK, na produção de citocinas com padrão Th1 (IL-2 e INF-g) e na liberação de TNF-a por células esplênicas, paralelamente a uma diminuição na produção de IL-10 (padrão Th2). Além disso, o tratamento com CV protegeu o hospedeiro da mielossupressão provocada pelo desenvolvimento tumoral, seja agindo diretamente na formação e manutenção do estroma medular, estimulando a atividade das células estromais, ou ainda estimulando a produção de citocinas reguladoras da hematopoese como a IL-6 e a IL-1a. Constatamos ainda que o tratamento com CV aumenta a atividade estimuladora de colônias (CSA) no soro de animais portadores de tumor e a capacidade proliferativa de células esplênicas. Outros resultados que merecem destaque são aqueles relacionados à ativação macrofágica. Nossos resultados demonstram que, em animais normais, o tratamento com CV promove aumento significativo nos níveis de TNF-a nos sobrenadantes das culturas de macrófagos peritoneais e esplênicos sem alterar a produção de IFN-g e IL-10. Além disso, o restabelecimento da produção normal de TNF-a, IFN-g e IL-10 por macrófagos peritoneais de animais portadores de TAE e reversão parcial dos efeitos produzidos pela presença do tumor na atividade dos macrófagos esplênicos, também foram observados. Outro efeito do CV sobre macrófagos peritoneais de animais portadores de TAE foi o estímulo da produção de H2O2 e NO2 -. Analisando nossos resultados podemos dizer que a CV além de possuir alto valor nutritivo, capacidade antioxidante e atividade anti-viral e antibacteriana, apresenta importante atividade imunomoduladora frente ao desenvolvimento tumoral, já que na presença do tumor o hospedeiro que vem recebendo Chlorella é capaz de reagir mais prontamente e com maior vigor na indução de mecanismos essenciais de defesa imunológica. Neste sentido, sugerimos que a alga Chlorella vulgaris pode ser um candidato a agente preventivo e complementar no tratamento do câncer. / Abstract: Chlorella vulgaris (CV) is a microscopic alga rich in nutrients. Besides the high nutritive value, this alga has shown important therapeutic properties. Many studies from our laboratory and others have shown the protective effects of CV against viral and bacterial infections, tumors, among others. In this work we evaluated the effects of the prophylactic/therapeutic treatment with a dose of 50 mg/Kg/day in normal and Ehrlich ascites tumor (EAT)-bearing mice. The study of the mechanisms involved in the protection produced by the CV against the EAT, induced alterations in the immune-hematopoietic system; demonstrating significant improvements in the NK cells activity, Th1 (IL-2 and INF-g) and TNF-a cytokines production by mononuclear spleen cells, concomitantly with the decrease of IL-10 (Th2) production. Moreover, treatment with CV protected the host of myelosuppression caused by tumor development, it is acting directly in the formation and maintenance of bone marrow stroma, by stimulating the activity of stromal cells, or stimulating the production of important hematopoiese regulatory cytokines like IL-6 and IL-1a. We are also certain that the treatment with CV increases the colony-stimulating activity (CSA) in the serum of tumor bearing mice and the proliferative capacity of spleen cells. Other results that deserve attention are those related to macrophage activation. Our results show that in normal mice, treatment with CV, promotes significant increase in the TNF-a levels in upernatants of the cultures of peritoneal and spleen macrophages without altering the production of IFN-g and IL-10. Moreover, restoration of the normal production of TNF-a, IFN-g and IL-10 by peritoneal macrophages from animal carriers of EAT and partial reversal of the effects produced by the presence of tumor in the splenic macrophages activity were also observed. Another effect of CV on peritoneal macrophages of tumor bearing mice was the stimulation in the production of NO2 - and H2O2. Looking at our results we can say that the alga Chorella vulgaris in addition to its high nutritional value, antioxidant capacity and antiviral and antibacterial activities, it also presents important immunomodulatory activity against tumor development, since that in the presence of the tumor, the host that has received Chlorella is able to react more promptly and with greater force in the induction of essential mechanisms of immune defense. Accordingly, we suggest that the alga Chlorella vulgaris can be a candidate for the preventive and complementary treatment of cancer by strengthening the immune system. / Doutorado / Farmacologia

La leucémie myéloïde chronique (LMC) est une hémopathie maligne causée par l‘apparition du chromosome Philadelphie dans la cellule souche hématopoïétique (CSH), conduisant à l‘expression de la protéine de fusion BCR-ABL1. L‘activité tyrosine kinase dérégulée de cette oncoprotéine provoque l‘activation de plusieurs voies de signalisation critiques dans la leucémogenèse. Si les inhibiteurs de tyrosine kinase (ITK) ciblant BCR-ABL1 représentent des traitements dans l'ensemble très efficaces, plusieurs études montrent que les cellules leucémiques les plus immatures de la moelle osseuse y sont insensibles. Cette thèse propose de compléter les connaissances relatives aux effets de BCR-ABL1 dans la cellule, et plus généralement aux propriétés des CSH de LMC. Notre intérêt s‘est focalisé sur le rôle potentiel des microARN. Dans un premier travail, nous nous sommes intéressés à l‘effet de l‘activité BCR-ABL1 sur le protéome et sur l‘expression des microARN dans la lignée cellulaire K562. Les résultats montrent que BCR-ABL1 régule l'expression d'un microARN fréquemment surexprimé dans les cancers, miR-21. Cet effet dépend du facteur de transcription STAT5, cible bien connue de l'activité kinase de BCR-ABL1. Dans une seconde partie, nous avons montré que dans la moelle osseuse des patients LMC, la fraction cellulaire enrichie en cellules souches (les cellules CD34+CD38low) exprime quatre microARN particuliers: mir-10a, mir-150, miR-155 et miR-146a. Deux de ces microARN (miR-150 et miR-155) sont trouvés spécifiquement dans les cellules des patients, et pas dans celles des individus sains. / In chronic myeloid leukemia (CML), the activity of the constitutively active tyrosine kinase BCR-ABL1 drives the activation of the PI3K/AKT, JAK/STAT, and RAS/RAF/MEK/ERK pathways. Among other consequences, activated or inhibited transcription factors induce important modifications of the CML cells gene expression pattern that could impact cell cycle control, apoptosis and genetic instability, leading to the expansion of the oncogene-transformed cells and to the acquisition of potentially harmful de novo mutations. However, indirect BCR-ABL1-dependant regulations might also occur, for instance through the action of microRNAs (miRNAs). Among the ~2000 miRNAs reported in humans, numerous species are up- or down-regulated in various cancer models. In the context of CML however, there is no clear consensus regarding the role of specific miRNAs, despite several studies. The first aim of this thesis was to study the effects of a clinically relevant concentration of imatinib, a tyrosine-kinase inhibitor (TKI) that blocks BCR-ABL1, on the CML cell line K562: both the microRNA expression profile and the cells proteome were analyzed. Using microarray hybridization, RT-qPCR experiments and a functional assay, we identified miR-21 as one of the most significantly down-regulated microRNA in cells that were treated with imatinib. In parallel, a semi-quantitative proteomic approach identified the tumor suppressor programmed cell death protein 4 (PDCD4) as the most over-expressed protein in imatinib-treated cells. We showed that miR-21 can bind to PDCD4 3'UTR and decrease its expression. The STAT5 - miR-21 - PDCD4 pathway was conserved in CML primary CD34+ cells, and to some extent in acute myeloid leukemia (AML) models as well; the known functions of miR-21 and PDCD4 suggest that their regulation by BCR-ABL1 could participate in the antileukemic response triggered by tyrosine kinase inhibitors. In the second part of this manuscript, we was interested in the immature stem cells population that cannot be eliminated by TKI. The underlying mechanisms of this resistance are not fully understood. The TKI-resistant CML stem cells reside in the CD34+/CD38low subpopulation, that can be sorted from the mononuclear cells fraction using FACS. In this project, we propose to describe the microRNA repertoire of the CML CD34+/CD38low cells to highlight the potential role of microRNA in the resistance mechanisms by identifying some of their targets, using bioinformatic and experimental approaches. This combination of miRNome and functional analysis would allow to increase the knowledge of the biology of the TKI-resistant CML stem cells. Our results have shown that the cellular fraction enriched in stem cells (CD34+CD38low) expressed specifically four microRNA: miR-10a, miR-146, miR-150 and miR-155. It is also interested to notice that only two of them, miR-150 and miR-155, are highly expressed in CML-patient CD34+CD38low cells compared to normal cells.

To find out if the haematopoietic system is common feature of vertebrates, we decided to examine haematopoiesis in a sea lamprey (Petromyzon marinus). All blood cells arises from the haematopoietic stem cells in higher vertebrates. We assume that this is common for the higher vertebrates and a jawless vertebrates, but nobody was interested in the jawless haematopoiesis since 1970. Using a reverse genetic, we identify homologues of important hematopoietic of higher vertebrates in transcriptome of the sea lamprey with emphasis on important receptors or transcription factors, because they can be used as the specific markers of different blood cells and their progenitors. Then we use those sequences for cloning, expression measurements and other work. We picked up sea lamprey as model organism because its unique phylogenetic position, important foe evo-devo studies, but also because lack of elementary knowledge about sea lamprey haematopoiesis. Key words: Petromyzon marinus, haematopoiesis, HSC, evo-devo

STAT5A et B sont des facteurs de transcription qui constituent le point de convergence de nombreux signaux extracellulaires. Parmi leurs fonctions biologiques, ils sont connus pour leur rôle dans le développement et la différentiation des cellules hématopoïétiques. Cependant, un taux d’activation et/ou d’expression élevé de ces protéines aboutit à une prolifération incontrôlée des cellules aboutissant ainsi à une leucémogenèse. Ce présent travail vise à caractériser des aptamères ADN (Apta1 et Apta2) sélectionnés préalablement au sein de notre laboratoire contre STAT5B afin de réguler son activité dans le contexte leucémique. Les aptamères ADN sont des oligonucléotides simple brin qui adoptent une structure 3D et interagissent de manière spécifique avec leurs cibles. Contrairement aux anticorps, ils sont peu immunogènes ; ils possèdent alors un potentiel thérapeutique intéressant. La première partie de ce projet se focalise sur l’étude de la capacité d’Apta1 et Apta2 à interagir avec la forme cellulaire et recombinante de STAT5B par pull down et calorimétrie à titrage isotherme. La seconde partie concerne l’évaluation de l’activité d’Apta2 par l’étude de son effet sur la viabilité d’un modèle de leucémie myéloïde chronique et sur sa capacité à perturber la voie de signalisation impliquant STAT5. / STAT5A and B are common transcription factors that constitute a convergent point for many cellular pathways. Among their multiple biological functions, they are well known in promoting immune cell development and differentiation. When some oncogenic mutations occur, STAT5A and B are highly activated leading to uncontrolled proliferation and then to leukemia. Thus, they constitute a prime target to therapeutic intervention. In this work, we characterize new DNA aptamers (Apta1 and Apta2) selected previously by our laboratory against STAT5B. DNA aptamers are single stranded DNA molecules that can adopt 3D structures and recognize specific targets. Unlike antibodies, they fail to induce the immune response: they emerge as potentiel therapeutic molecules. In the first part of this work, the selected aptamers were assessed on their ability to interact with the cellular and recombinant form of STAT5B by using pull down assay and Isothermal Titration Calorimetry. In the second part, we focused on evaluating the effect of Apta2 on chronic myeloid leukemia cell line. For this purpose, cell viability, apoptosis process and JAK-STAT5 signaling pathway were depicted when cells are treated with Apta2.

Evidências sobre a presença do sistema renina-angiotensina (SRA) na medula óssea e a possível participação da enzima conversora de angiotensina-I (ECA) na regulação hematopoética tem despertado o interesse da comunidade científica. Como a ECA também é um componente chave do sistema calicreína-cininas (SCC), é possível que elementos deste sistema, possam estar envolvidos no controle hematopoético. Assim, avaliamos a participação da ECA na regulação hematopoética de animais não modificados (WT) e nocautes dos receptores B1 de cininas (KOB1). Para isso, utilizamos técnicas de cultura de células de medula óssea, a saber: os ensaios clonogênicos em soft-ágar para granulócitos e macrófagos (CFU-GM) e o sistema de cultura líquida de longa duração (CLLD). Os resultados mostraram a presença da ECA em células das CLLD e indicaram a participação da enzima na proliferação de progenitores hematopoéticos possivelmente através do controle dos níveis de AcSDKP, pois o tratamento com o tetrapeptídeo e com captopril, reduziu significativamente o número CFU-GM in vitro e in vivo. Quando adicionado às CLLD, o AcSDKP foi capaz de aumentar significativamente a expressão do mRNA da ECA, sugerindo que seus níveis possam controlar a expressão gênica desta enzima. Em relação aos animais KOB1, os resultados mostraram maior atividade da ECA, acompanhado de aumento não significativo da expressão gênica e protéica da enzima. O tratamento das CLLD de animais WT com agonistas de receptores de cininas, não alterou a expressão gênica e a atividade da ECA. Assim, nossos dados sugerem que a ECA participa da regulação hematopoética neste modelo. No entanto, novos estudos serão necessários para a elucidação dos mecanismos envolvidos na expressão e/ou controle da atividade da ECA pelos receptores de cininas. / Evidences on the presence of the renin angiotensin system in the bone marrow and the possible participation of the angiotensin-I converting enzyme (ACE) in the hematopoietic regulation have aroused interest of the scientific community. As the ACE also is a common element of the kallikrein-kinin system (KKS), it is possible that elements of KKS, can be involved in the hematopoietic control. Thus, we evaluated the participation of the ACE on the hematopoietic regulation of wild-type (WT) and kinin receptor B1 knockout mice (KOB1). For this, we use techniques of bone marrow cell culture, to know the clonogenic assays for granulocyte-macrophage (GM-CFU) and the long term bone marrow cultures (LTBMC). The results shown the presence of the ACE in cells from LTBMC and its possible participation on hematopoietic proliferation through the control of AcSDKP levels, therefore the treatment with AcSDKP and captopril, decreased significantly the GM-CFU number in vitro and in vivo. When added to the LTBMC, the AcSDKP increase significantly the expression of ACE mRNA, suggesting that its levels could control the gene expression of this enzyme. In relation to KOB1 mice, the results shown increase of the ACE activity and not significant increase of the gene and protein expression of the enzyme. The treatment of the LTBMC of WT mice with kinins receptors agonists, did not modify the gene expression and the ACE activity. Thus, our data suggesting that ACE participate of the hematopoietic regulation in this model. However, new studies will be necessary to understand the involved mechanisms in the expression and/or control of ACE activity by kinins receptors.

Hematopoiesis has been for many years seen as a straightforward process based on sequential restriction of cell fate potential leading to production of mature blood cells. In the last decade, however, several works documented an unexpected plasticity of hematopoietic cells with expanded potential of myeloid development from lymphoid progenitors and vice versa. Under physiologic conditions hematopoiesis is tightly controlled and the definite cell fate is denominated by multiple factors that all lead to changes in regulatory networks that include transcription factors, epigenetic changes and post-transcriptional modulations. Any disruption of this strict regulation, caused by mutations or other events, affects the proliferation and lineage fidelity of hematopoietic precursors. This may lead to clonal growth of variable significance or leukemogenesis and may possibly affect the treatment sensitivity of the hematological malignancies. For better understanding of hematopoietic regulation we described gene expression changes during physiological development of lymphoid and myeloid lineages and in leukemic specimens using our own simplified real-time PCR based platform. We investigated expression of 95 genes connected with lymphoid and myeloid differentiation or with leukemogenesis in sorted hematopoietic...

La santé cardiovasculaire, la fonction immunitaire, l'hémostase et la réponse à d'autres maladies dépendent de l'abondance et des caractéristiques spécifiques des cellules sanguines. Au fil des années, un effort considérable a été fait pour trouver les variants génétiques, les gènes et les mécanismes de régulation impliqués dans la création de ces cellules. L'inactivation d'un allèle, appelée "perte de fonction" (LoF), est un type de variant codant que nous aimerions associer aux phénotypes sanguins. Comme ces mutations ne peuvent pas être artificiellement induites chez l'humain, pour des raisons éthiques évidentes, nous observons les occurences naturelles de ces pertes de fonction et espérons que la taille des cohortes sera suffisante pour trouver des associations statistiquement significatives. L'inactivation des deux allèles, appelée "knockout" (KO), peut avoir des conséquences plus fortes qu'une simple perte de fonction. Nous espérons également trouver des KO d'origine naturelle grâce à la taille des cohortes. La combinaison de deux variants LoF différents sur les deux allèles est appelée knockout hétérozygote composé. Nous nous intéressons également aux variants non codants qui affectent l'expression des gènes impliqués dans l'hématopoïèse. Certains de ces variants créent ou perturbent des sites de liaison des facteurs de transcription (TF), ces protéines qui se lient à des séquences d'ADN spécifiques et régulent l'expression des gènes. Les sites de liaison (TFBS) des facteurs de transcription se trouvent dans les promoteurs des gènes et dans les amplificateurs spécifiques au type cellulaire. Alors que certaines de ces mutations peuvent être bénignes ou même bénéfiques, la présence d'un LoF ou d'un KO peut être trop nuisible à la survie de l'individu. Les résultats de cette étude sont limités par le biais de survie. Comparée à une étude d'association pangénomique, cette étude se concentre sur un plus petit nombre de variants génétiques pour augmenter la puissance statistique et offrir une interprétation pour les résultats statistiquement significatifs. Le programme Trans-Omics for Precision Medicine (TOPMed) recueille et garantit la qualité des 45 000 séquences du génome entier que nous avons utilisées dans cette étude, ainsi que les bilans sanguins correspondants. Grâce à ces données, nous avons pu trouver plusieurs associations connues et nouvelles entre des variants rares et des phénotypes sanguins. / Cardiovascular health, immune function, hemostasis and the response to other illnesses depend on the abundance and specific features of blood cells. Over the years, a considerable effort has been made to find which genetic variants, genes and regulatory mechanisms are involved in the creation of these cells. The inactivation of an allele, called a loss-of-function (LoF), is a type of coding variant we would like to associate with blood phenotypes. For obvious ethical reasons, these mutations cannot be artificially induced in human, so we fall back on natural occurrences and hope that large cohorts will provide enough samples to find statistically significant associations. The inactivation of both alleles, called a knockout (KO), may have stronger consequences than a simple loss-of-function. We also hope to find naturally occurring knockouts thanks to the size of a large cohort. The combination of two different LoF variants is called a compound heterozygote knockout. We are also interested in non-coding variants that affect the expression of genes that are involved in hematopoiesis. Some of these variants create or disrupt the binding sites of transcription factors (TF), the proteins that bind to specific DNA sequences and regulate gene expression. Transcription factors binding sites (TFBS) are found in gene promoters and cell type specific enhancers. While some of these mutations can be benign or even beneficial, the presence of a LoF or KO may be too detrimental for the individual to survive. The results of this study are limited by survival bias. Compared to a genome-wide association study, this study focuses on a smaller number of genetic variants to increase statistical power and give an interpretation to the statistically significant findings. The Trans-Omics for Precision Medicine (TOPMed) program collects and ensures the quality of the 45,000 whole-genome sequences we used in this study, as well as the corresponding complete blood counts. Thanks to this raw data, we were able to find several known and novel associations between rare variants and blood phenotypes.

Costimulation blockade based on a donor-specific transfusion and anti-CD154 mAb is effective for establishing mixed allogeneic hematopoietic chimerism and inducing transplantation tolerance. Despite its potential, recent evidence suggests that the efficacy of costimulation blockade can be reduced by environmental perturbations such as infection or inflammation that activate toll-like receptors (TLR). TLR agonists prevent costimulation blockade-induced prolongation of solid organ allografts, but their effect on the establishment of hematopoietic chimerism has not been reported. In this dissertation, we hypothesized that TLR activation during costimulation blockade would prevent the establishment of mixed hematopoietic chimerism and shorten skin allograft survival. To test this hypothesis, costimulation blockade-treated mice were co-injected with TLR2 (Pam3Cys), TLR3 (poly I:C), or TLR4 (LPS) agonists and transplanted with allogeneic bone marrow and skin grafts. Supporting our hypothesis, we observed that TLR agonists administered at the time of costimulation blockade prevented the establishment of mixed hematopoietic chimerism and shortened skin allograft survival. To investigate underlying cellular and molecular mechanisms, we first determined that LPS administration during costimulation blockade did not increase production of alloantibodies or activate natural killer cells. Similarly, costimulation blockade-treated mice depleted of CD4+ or CD8+ cells did not become chimeric when co-injected with LPS. In contrast, mice depleted of both CD4+ and CD8+cell subsets were resistant to the effects of LPS. We next observed that alloreactive T cells were activated by TLR agonists in mice treated with costimulation blockade, and this activation correlated with LPS-induced maturation of donor and host alloantigen-presenting cells. In contrast, TLR4-deficient mice treated with costimulation blockade and LPS did not upregulate costimulatory molecules on their APCs, and mixed chimerism and permanent skin allograft survival were readily achieved. We further observed that injection of recombinant IFN-β recapitulated the detrimental effects of LPS, and that LPS-injected mice deficient in the type I IFN receptor were partially protected. Importantly, alloantigen-presenting cells did not upregulate costimulatory molecules in response to LPS, and mixed chimerism and permanent skin allograft survival were readily established in type I IFN receptor and MyD88 double deficient mice treated with costimulation blockade. We conclude that the TLR4 agonist LPS prevents the establishment of mixed hematopoietic chimerism and shortens skin allograft survival in mice treated with costimulation blockade by inducing the production of type 1 IFN and MyD88-dependent factors that upregulate costimulatory molecules on APCs, leading to the generation of activated alloreactive T cells.

Runx1 is a master regulator of hematopoiesis, required for the initiation of definitive hematopoiesis in the embryo and essential for appropriate differentiation of many hematopoietic lineages in the adult. The roles of Runx1 in normal hematopoiesis are juxtaposed with the high frequency of Runx1 mutations and translocations in leukemia. Leukemia associated Runx1 mutations that retain DNA-binding ability have truncations or frame shifts that lose C-terminal domains. These domains are important for subnuclear localization of Runx1 and protein interactions with co-factors. The majority of leukemia associated Runx1 translocations also replace the C-terminus of Runx1 with chimeric fusion proteins. The common loss of Runx1 C-terminal domains in hematopoietic diseases suggests a possible common mechanism. We developed a panel of mutations to test the functions of these domains in vitro, and then developed mouse models to examine the consequences of losing Runx1 C-terminal domains on hematopoietic development and leukemogenesis in vivo. We previously observed that overexpression of a subnuclear targeting defective mutant of Runx1 in a myeloid progenitor cell line blocks differentiation. Gene expression analysis before differentiation was initiated revealed that the mutant Runx1 was already deregulating genes important for maturation. Furthermore, promoters of the suppressed genes were enriched for binding sites of known Runx1 co-factors, indicating a non-DNA-binding role for the mutant Runx1. To investigate the in vivo function of Runx1 C-terminal domains, we generated two knock-in mouse models; a C-terminal truncation, Runx1Q307X, and a point mutant in the subnuclear targeting domain, Runx1 HTY350-352AAA . Embryos homozygous for Runx1 Q307X phenocopy a complete Runx1 null and die in utero from central nervous system hemorrhage and lack of definitive hematopoiesis. Embryos homozygous for the point mutation Runx1HTY350-352AAA bypass embryonic lethality, but have hypomorphic Runx1 function. Runx1HTY350-352AAA results in defective growth control of hematopoietic progenitors, deregulation of B-lymphoid and myeloid lineages, as well as maturation delays in megakaryocytic and erythroid development. Runx1 localizes to subnuclear domains to scaffold regulatory machinery for control of gene expression. This work supports the role of transcription factors interacting with nuclear architecture for greater biological control, and shows how even subtle alterations in that ability could have profound effects on normal biological function and gene regulation.

No description available.